Mark For: OMEROS™ trademark registration is intended to cover the categories of pharmaceuticals, namely surgical and burn management solutions containing pharmacologic agents for the inhibition of pain, inflammation, cartilage loss, smooth muscle spasm and tumor cell adhesion; intravascular solutions containing pharmacologic agents for the inhibition of vasospasm and restenosis; drug delivery systems, namely combinations of pharmacologic agents or genes and their carriers for the treatment and inhibition of pain, inflammation, cartilage loss, smooth muscle spasm, tumor cell adhesion, vasospasm and restenosis.
Status
2023-12-10 UTC
DEAD APPLICATION Refused Dismissed or Invalidated
This trademark application was refused, dismissed, or invalidated by the Office and this application is no longer active.
(Pharmaceuticals) Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
Filed Use
No
Current Use
No
Intent To Use
Yes
Filed ITU
Yes
44D Filed
No
44E Current
No
66A Current
No
Current Basis
No
No Basis
No
Attorney Name
Marcia S. Kelbon
Attorney Docket Number
OMER221306
Law Office Assigned
L80
Employee Name
COFIELD, JULIA HARDY
Timeline
1999-08-20
Application Filed
2000-04-25
Published
2000-04-25
Published for Opposition
2002-07-19
Abandon
2002-07-19
Status: Abandoned because no Statement of Use or Extension Request timely filed after Notice of Allowance was issued. To view all docume
MARCIA S KELBON CHRISTENSEN O'CONNOR JOHNSON ET AL 1420 5TH AVE STE 2800 SEATTLE WA 98101-1344
Good, Services, and Codes
International Codes:
5
U.S. Codes:
006,018,044,046,051,052
International Codes:
10
U.S. Codes:
026,039,044
Type Code
Type
GS0051
pharmaceuticals, namely surgical and burn management solutions containing pharmacologic agents for the inhibition of pain, inflammation, cartilage loss, smooth muscle spasm and tumor cell adhesion; intravascular solutions containing pharmacologic agents for the inhibition of vasospasm and restenosis; drug delivery systems, namely combinations of pharmacologic agents or genes and their carriers for the treatment and inhibition of pain, inflammation, cartilage loss, smooth muscle spasm, tumor cell adhesion, vasospasm and restenosis
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.